Form 4: Celularity Executive John Haines Reports RSU Vesting

Senior Executive Vice President John Haines acquired 1,641 shares of Celularity Inc. through the vesting of restricted stock units.

Summary

• John R. Haines, Senior Executive Vice President of Celularity Inc., converted 1,641 restricted stock units (RSUs) into Class A common stock on April 13, 2026.
• The transaction involved a tax withholding event where 583 shares were withheld at a price of $1.28 per share.
• Following these transactions, the reporting person holds 30,179 shares of Class A common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents the routine fulfillment of previously granted executive compensation packages.

Positives

• The transaction represents the scheduled vesting of equity compensation, indicating alignment between executive interests and long-term company performance.

Negatives

• The company withheld 583 shares to cover tax obligations associated with the RSU vesting, which is a standard but dilutive event for the individual's holdings.

Risks

• The value of the equity is subject to market volatility, as evidenced by the $1.28 per share valuation used for tax withholding.

Future Outlook

No specific forward-looking guidance was provided in this filing, as it is a standard disclosure of changes in beneficial ownership.

Industry Context

StockSavvy.ai notes that this filing is a routine disclosure of executive compensation vesting, which is common in the biotechnology sector to retain key leadership talent.

Comparison to Industry Standards

• The use of RSU vesting as a component of executive compensation is consistent with standard practices for publicly traded biotech firms like Celularity.
• Tax withholding via share reduction is a standard administrative procedure for equity-based compensation plans.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity vesting event for an existing executive.

Next Steps

• No future actions or milestones were disclosed in this filing.

Key Dates

Keywords

CELU, Celularity, Insider Trading, Form 4, Equity Compensation, Biotech